Dr. Gasparetto on Efficacy of Selinexor Combination in Multiple Myeloma

Cristina Gasparetto, MD
Published: Thursday, Feb 01, 2018



Cristina Gasparetto, MD, assistant professor of medicine, member of the Duke Cancer Institute, discuss the efficacy of selinexor in combination with dexamethasone  and daratumumab (Darzalex) for the treatment of patients with multiple myeloma.

This combination is not approved by the FDA but researchers are still accumulating data, explains Gasparetto. Both are being investigated in phase III trials, creating potential for 2 additional drugs for the treatment of patients with multiple myeloma.

The number of patients treated on the combination study was very small, but Gasparetto says that the community is excited about the signal the treatment is showing. Selinexor was previously investigated in combination with dexamethasone in refractory patients with multiple myeloma, where it showed efficacy as a single-agent.

In this trial, selinexor combined with weekly bortezomib (Velcade) and low-dose dexamethasone produced rapid and durable responses in a dose escalation/expansion trial of patients with relapsed/refractory multiple myeloma. The overall response rate was 84% in patients who had relapsed after a proteasome inhibitor (PI) or were naïve to a PI, and 43% in patients whose disease was refractory to a PI.
 


Cristina Gasparetto, MD, assistant professor of medicine, member of the Duke Cancer Institute, discuss the efficacy of selinexor in combination with dexamethasone  and daratumumab (Darzalex) for the treatment of patients with multiple myeloma.

This combination is not approved by the FDA but researchers are still accumulating data, explains Gasparetto. Both are being investigated in phase III trials, creating potential for 2 additional drugs for the treatment of patients with multiple myeloma.

The number of patients treated on the combination study was very small, but Gasparetto says that the community is excited about the signal the treatment is showing. Selinexor was previously investigated in combination with dexamethasone in refractory patients with multiple myeloma, where it showed efficacy as a single-agent.

In this trial, selinexor combined with weekly bortezomib (Velcade) and low-dose dexamethasone produced rapid and durable responses in a dose escalation/expansion trial of patients with relapsed/refractory multiple myeloma. The overall response rate was 84% in patients who had relapsed after a proteasome inhibitor (PI) or were naïve to a PI, and 43% in patients whose disease was refractory to a PI.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x